Vaccines

PATHOQUEST SOLUTION

PathoQuest can help characterize, QC and release your vaccines across the manufacturing journey

DISCOVERY

PRE-CLINICAL

PHASE 1

PHASE 2

PHASE 3

MARKET

Cell line selection

Viral seed selection

Cell line characterization – MCB, WCB, End of Production

Viral seed stock characterization

In-process testing – bulk harvest lot release, biosafety and viral testing

Final product release testing – identity testing

Plasmid identity testing and raw material screening

Investigatory support

PATHOQUEST SOLUTION

PathoQuest can help characterize, QC and release your vaccines across the manufacturing journey

OUR EXPERTISE

PathoQuest addresses the assay compatibility and timeline challenges faced by vaccine developers and manufactures through the application of our expert GMP NGS services. We have worked across vaccine platforms, from established recombinant and inactivated vaccine technologies to the emerging RNA and viral vector vaccine platforms. Our GMP level NGS services are supported by industry leading expert bioinformatic analysis, giving you ultimate confidence in the analysis of the results. 

PathoQuest actively participates in regulatory and expert industry interest groups, associations and consortia, as well as frequently publishing in peer-reviewed journals. We lead the way in both innovation as well as acceptance of NGS technology in characterization and release testing across biologics (specifically for vaccine applications).

CHALLENGES SOLVED

PathoQuest addresses the key challenges you face in manufacturing and releasing your vaccine by addressing key concerns:

  • Faster cell line and viral seed development and selection with deeper genetic insights
  • De-risking your manufacturing process by rapidly screening critical raw materials such as serum and plasmids
  • Reducing the cell line and viral seed characterization bottleneck, allowing you to get your vaccine to patients faster
  • Removing the need for neutralizing antibody which can be difficult and time-consuming to generate for vaccines
  • Meeting corporate 3Rs ethical objectives by removing animal models

Modalities

mAbs and Recombinants

Bacterial and mammalian produced proteins, hormones and peptides

READ MORE

Viral Vectors

Viral gene delivery, oncolytic and immunotherapy including manufacturing plasmids

READ MORE

Cell Therapies

Including gene modified, or unmodified stem cell therapies, allogeneic or autologous

READ MORE

Vaccines

Inactivated, live-attenuated, recombinant, RNA and viral vector products

READ MORE

RNA

Immunotherapies, antiviral, vaccines, RNAi and CRISPR based gene editing

READ MORE

Cultivated Meat

Engineered cells and tissues cultured in more ethical in vitro environments

READ MORE

Contact us

U.S.

+1 484 212 9360

466 Devon Park Dr
Wayne, PA 19087
United States

Sign up for our latest news

France

+33 (0)1 70 82 17 90

Biopark -Bâtiment B,
11, rue Watt
75013 Paris, France

How can PathoQuest help?

Name(Required)
This field is for validation purposes and should be left unchanged.

U.S.

+1 484 212 9360

466 Devon Park Dr
Wayne, PA 19087
United States

France

+33 (0)1 70 82 17 90

Biopark -Bâtiment B,
11, rue Watt
75013 Paris, France

How can PathoQuest help?

Name(Required)
This field is for validation purposes and should be left unchanged.

Sign up for our latest news